A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

The Drug Information Association (DIA) today announced the launch of DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its ...

Biotech is dominating the (very) early 2026 deals market, whether that be startup fundings, IPOs, or mergers. Why it matters: ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

As venture funding becomes more selective, thoughtful decision-making and careful use of capital are becoming advantages in the startup landscape, especially for companies centered around life ...

The University of Pennsylvania, German biotech firm BioNTech, and Osage University Partners, a Bala Cynwyd venture capital ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best set yourself up for success, adapt your approach to the specific scientific ...

Kathy Hochul on Tuesday unveiled four new initiatives to support biotech startups and accelerate drug development in New York ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...